Literature DB >> 15833881

Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

Virginia G Kaklamani1, Lisa Baddi, Junjian Liu, Diana Rosman, Sharbani Phukan, Ciarán Bradley, Chris Hegarty, Bree McDaniel, Alfred Rademaker, Carole Oddoux, Harry Ostrer, Loren S Michel, Helen Huang, Yu Chen, Habibul Ahsan, Kenneth Offit, Boris Pasche.   

Abstract

There is growing evidence that common variants of the transforming growth factor-beta (TGF-beta) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-beta signaling, whereas others have an opposite effect. We tested the hypothesis that a combined genetic assessment of two well-characterized variants may predict breast cancer risk. Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-beta circulating levels. Cases and controls were of similar ethnicity and geographic location. Thirty percent of cases were identified as high or low TGF-beta signalers based on TGFB1 and TGFBR1 genotypes. There was a significantly higher proportion of high signalers (TGFBR1/TGFBR1 and TGFB1*CC) among controls (21.6%) than cases (15.7%; P = 0.003). The odds ratio [OR; 95% confidence interval (95% CI)] for individuals with the lowest expected TGF-beta signaling level (TGFB1*TT or TGFB1*TC and TGFBR1*6A) was 1.69 (1.08-2.66) when compared with individuals with the highest expected TGF-signaling levels. Breast cancer risk incurred by low signalers was most pronounced among women after age 50 years (OR, 2.05; 95% CI, 1.01-4.16). TGFBR1*6A was associated with a significantly increased risk for breast cancer (OR, 1.46; 95% CI, 1.04-2.06), but the TGFB1*CC genotype was not associated with any appreciable risk (OR, 0.89; 95% CI, 0.63-1.21). TGFBR1*6A effect was most pronounced among women diagnosed after age 50 years (OR, 2.20; 95% CI, 1.25-3.87). This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833881     DOI: 10.1158/0008-5472.CAN-04-2961

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Authors:  Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu
Journal:  Carcinogenesis       Date:  2011-04-22       Impact factor: 4.944

2.  Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer.

Authors:  Xiaoxiang Guan; Erich M Sturgis; Dapeng Lei; Zhensheng Liu; Kristina R Dahlstrom; Qingyi Wei; Guojun Li
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 3.  Recent advances in breast cancer genetics.

Authors:  Boris Pasche
Journal:  Cancer Treat Res       Date:  2008

Review 4.  The complexities of TGF-β action during mammary and squamous cell carcinogenesis.

Authors:  Erin C Connolly; Rosemary J Akhurst
Journal:  Curr Pharm Biotechnol       Date:  2011-12       Impact factor: 2.837

5.  Impact of TGF-β1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis.

Authors:  Joana Vieira de Castro; Céline S Gonçalves; Sandra Costa; Paulo Linhares; Rui Vaz; Ricardo Nabiço; Júlia Amorim; Marta Viana-Pereira; Rui M Reis; Bruno M Costa
Journal:  Tumour Biol       Date:  2015-03-27

6.  Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.

Authors:  Qinghua Zeng; Sharbani Phukan; Yanfei Xu; Maureen Sadim; Diana S Rosman; Michael Pennison; Jie Liao; Guang-Yu Yang; Chiang-Ching Huang; Laura Valle; Antonio Di Cristofano; Albert de la Chapelle; Boris Pasche
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  A functional polymorphism of TGFBR2 is associated with risk of breast cancer with ER(+), PR(+), ER(+)PR(+) and HER2(-) expression in women.

Authors:  Mei Zhang; Ling-Ling Guo; Zhongqin Cheng; Reng-Yun Liu; Yufeng Lu; Qian Qian; Zhe Lei; Hong-Tao Zhang
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

8.  Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia.

Authors:  Barbara S Saltzman; Jennifer F Yamamoto; Robert Decker; Lance Yokochi; Andre G Theriault; Thomas M Vogt; Loïc Le Marchand
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

9.  TGFBR1*6A/9A polymorphism and cancer risk: a meta-analysis of 13,662 cases and 14,147 controls.

Authors:  Ru-Yan Liao; Chen Mao; Li-Xin Qiu; Hong Ding; Qing Chen; Hai-Feng Pan
Journal:  Mol Biol Rep       Date:  2009-11-01       Impact factor: 2.316

10.  Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes.

Authors:  Núria Bonifaci; Antoni Berenguer; Javier Díez; Oscar Reina; Ignacio Medina; Joaquín Dopazo; Víctor Moreno; Miguel Angel Pujana
Journal:  BMC Med Genomics       Date:  2008-12-18       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.